Erin Dwyer

Erin Dwyer serves as a key procurement professional within the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, where she manages acquisitions that advance scientific research into substance use disorders. Her work centers on securing specialized scientific, technical, and laboratory services essential to translating neurobiological and behavioral research into clinical and public health applications. She oversees contracts supporting cutting-edge research infrastructure, analytical instrumentation, and professional scientific services, ensuring alignment with NIDA’s mission to fund innovation in addiction science. Her acquisitions typically involve complex, high-precision research tools and multi-institutional collaborative studies. Dwyer maintains strong, recurring partnerships with leading academic medical institutions, including McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These relationships reflect a pattern of sustained collaboration with research-intensive universities and affiliated clinical centers engaged in NIH-funded studies. Her contracting approach emphasizes long-term scientific continuity, often supporting multi-year research initiatives that require specialized expertise in neuroimaging, behavioral analysis, and translational drug development. Her procurement portfolio is predominantly open competition, with 81.8% of awards issued without set-asides, reflecting the technical complexity and specialized nature of the required services. However, she consistently allocates 18.2% of awards to total small business set-asides under FAR 19.5, demonstrating a measured commitment to small business participation without compromising scientific rigor. Dwyer’s primary NAICS focus lies in analytical laboratory instrument manufacturing (334516) and professional scientific services (541990), underscoring her expertise in procuring high-end research equipment such as mass spectrometers, neuroimaging systems, and behavioral monitoring platforms. She also supports research and development in life sciences (541715) and hospital-based clinical research (622110), reflecting a technical domain centered on evidence-based addiction science and translational biomedical innovation.